Amylyx Pharmaceuticals (AMLX) Share-based Compensation (2021 - 2026)

Amylyx Pharmaceuticals' Share-based Compensation history runs 6 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 10.43% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $26.9 million (down 10.07% YoY), while the FY2025 annual figure was $27.6 million, down 16.32% from the prior year.
• Share-based Compensation was $6.1 million for Q1 2026 at Amylyx Pharmaceuticals, down from $6.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.2 million in Q3 2023 to a low of $4.4 million in Q1 2022.
• Historically, Share-based Compensation has averaged $7.4 million across 5 years, with a median of $6.8 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 768.65% in 2022, then sank 33.15% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $6.1 million in 2022, then jumped by 56.53% to $9.5 million in 2023, then declined by 29.3% to $6.7 million in 2024, then slipped by 5.27% to $6.4 million in 2025, then retreated by 4.17% to $6.1 million in 2026.
• The last three Share-based Compensation figures came in at $6.1 million (Q1 2026), $6.4 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.